RECRUITING

RFA Treatment for Papillary Thyroid Microcarcinoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively. The purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.

Official Title

RFA Treatment for Papillary Thyroid Microcarcinoma Cohort

Quick Facts

Study Start:2021-11-01
Study Completion:2026-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05189821

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients (\>/= 18 years)
  2. * Biopsy proven papillary thyroid microcarcinoma (\>/= 1.5cm in greatest diameter, PTMC)
  3. * Either refuse surgery or are not good surgical candidates
  1. * Cardiac arrhythmia
  2. * Pregnancy

Contacts and Locations

Study Contact

Jennifer H Kuo, MD MS
CONTACT
212-305-6969
jhk2029@cumc.columbia.edu
Vilma Rosario
CONTACT
vr2222@cumc.columbia.edu

Principal Investigator

Jennifer H Kuo, MD MS
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Columbia University
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Jennifer H Kuo, MD MS, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-01
Study Completion Date2026-11

Study Record Updates

Study Start Date2021-11-01
Study Completion Date2026-11

Terms related to this study

Keywords Provided by Researchers

  • Radiofrequency Ablation

Additional Relevant MeSH Terms

  • Papillary Thyroid Microcarcinoma